Form 4: Inhibikase Therapeutics Director Reports Stock Transaction
Insider Transaction (Form 4)
Dennis N Berman, a Director of Inhibikase Therapeutics, Inc., reported multiple transactions in common stock on July 30, 2026.
Summary
- Option exercise/conversion: acquired 21,854 Common Stock at $1.26 ($27,536) on July 30, 2026; holds 21,854 after (Direct).
- Option exercise/conversion: disposed of 21,854 Stock Option (Right to Buy) on July 30, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Dennis N Berman — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-30 | Option exercise/conversion | Common Stock | 21,854 | $1 | $27.5K | 21,854 |
| 2026-07-30 | Option exercise/conversion | Stock Option (Right to Buy) | 21,854 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-30 | Option exercise/conversion (21,854 shares) |
| 2026-07-30 | Option exercise/conversion (21,854 shares) |
Keywords
insider transaction, Form 4, IKT, Inhibikase Therapeutics, Inc., neutral, Dennis N Berman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.